Document is current

Any future updates will be listed below

Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications

Crossref DOI link: https://doi.org/10.1007/s40262-016-0405-4

Published Online: 2016-05-21

Published Print: 2016-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark